The global pharmaceutical packaging sector is entering a decisive phase of transformation. As pipelines fill with targeted therapies, biologics, and complex drug-device combinations, the role of packaging is expanding well beyond protection and compliance. It now encompasses agility, patient usability, sustainability, and digital traceability – all under mounting regulatory and cost pressures.

According to Grand View Research, the global pharmaceutical packaging market was valued at USD 139 billion in 2023 and is projected to reach USD 265 billion by 2030 – a CAGR of 9.7%. The contract packaging segment alone is expected to double within a decade, reflecting pharma’s growing reliance on outsourcing partners for specialised expertise.

This expansion is matched by complexity. Accelerated development timelines, smaller patient populations, and diverse global markets are reshaping packaging operations from a linear process into a strategic discipline. Whether for oral solid dose (OSD) forms or injectables and drug-device combinations, the common denominator is the need for integrated, flexible, and compliant packaging solutions that can adapt quickly to scientific and commercial realities.

Agility and Late-Stage Customisation in Oral Solid Dose Packaging

Traditional packaging strategies were built around scale: long production runs, stable SKUs, and predictable demand. That model is increasingly unfit for purpose in a world of precision medicines and regionalised launches. A more adaptive framework – often referred to as Late-Stage Customisation (LSC) – is now emerging as an industry best practice.

LSC allows manufacturers and CDMOs to postpone the final printing, labelling, or configuration of packaging until demand is clearer or regional destinations are confirmed. Digital printing technologies make this possible: rather than producing large volumes of pre-printed components,

Companies can maintain a neutral “brite stock” and add variable data, artwork, and language versions at the final stage. It is important to establish the highest common denominator of the core component – whether that is a nude blister, an assembled device, or another base configuration – so manufacturers can still capitalise on larger-volume runs for that shared element while applying appropriately scaled, flexible techniques for market-specific or even named-patient customisation.

This approach tackles what engineers sometimes call the “trumpet syndrome” – where complexity widens downstream as multiple SKUs, languages, and regulatory variants accumulate. Late-stage flexibility narrows that funnel.

The benefits extend across the product lifecycle:

• Reduced waste and inventory – fewer obsolete printed components and more efficient warehouse utilisation.
• Accelerated speed-to-market – particularly for drugs with short shelf lives or limited stability data.
• Enhanced compliance – real-time adaptation to regulatory or language changes.
• Improved working capital – less money tied up in pre-configured packaging stock.